Responsible for the development and implementation of the Cell Therapy Development (CTD) strategy initiatives for US-site operations , Bristol Myers Squibb. Current responsibilities include the development of IT solutions for proficient capital expenditure tracking and the harmonization of resource initiatives. In addition, I have successfully supported the Portfolio Strategy and Integration (PSI) team by leading product development activities for CMC and biologic portfolio opportunities.

Responsible for the management of the quality components associated with commercial readiness programs including suitability assessments of third party suppliers and product launch readiness. Point lead for combination product remediation program for Novartis/Sandoz portfolios.

Senior manager responsible for early phase development activities for complex injectable generic product portfolio. Internal evaluation point lead for development partner oversight and contract management. Team lead for development activities up through filing including regulatory response management and commercial readiness.